- Home
- KPTI vs RNA Comparison
KPTI vs RNA Comparison
Compare KPTI & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPTI | RNA |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | 228 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.8M | 199.7M |
| IPO Year | 2013 | 2025 |
Fundamental Metrics
Financial Performance| Metric | KPTI | RNA |
|---|---|---|
| Price | $8.63 | $13.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 20 |
| Target Price | $16.00 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 403.3K | 311.0K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,067,000.00 | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | $22.36 | $18.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $3.65 | $11.95 |
| 52 Week High | $10.99 | $73.06 |
Technical Indicators
Market Signals| Indicator | KPTI | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 34.84 |
| Support Level | $8.11 | $13.06 |
| Resistance Level | $9.00 | $14.80 |
| Average True Range (ATR) | 0.58 | 0.60 |
| MACD | -0.03 | 0.53 |
| Stochastic Oscillator | 33.12 | 26.51 |
Price Performance
Historical ComparisonAbout KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.